Initial 17β‐Estradiol Dose for Treating Vasomotor Symptoms

  title={Initial 17$\beta$‐Estradiol Dose for Treating Vasomotor Symptoms},
  author={Morris Notelovitz and John Lenihan and Michele Mcdermott and Irwin J Kerber and Joan Carles Arce},
  journal={Obstetrics \& Gynecology},

Figures and Tables from this paper

Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial

  • H. HonjoY. Taketani
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2009
The dose of 0.5 mg/day was effective as the oral E2 starting dose for treatment of hot flushes in Japanese women, and the higher E2 dose showed more pronounced effects on symptom severity.

Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief

The data show that both ultra-low-dose regimens are effective in reducing the severity and number of hot flushes compared to placebo, with good safety profiles.

Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China

This ultra-low-dose regimen provides an additional option for women experiencing the vasomotor symptoms of menopause and is consistent with previous results in other populations.

Identifying meaningful differences in vasomotor symptoms among menopausal women

Among menopausal women with moderate to severe vasomotor symptoms, the treatment satisfaction thresholds that were meaningful to participants were 1.64 fewermoderate to severe hot flushes per day and 0.42 fewer nighttime awakenings per night.

0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes

Effective relief from hot flushes can be reached within 12 weeks with estradiol doses of 0.5 and 1 mg in combination with different drospirenone doses.

A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17&bgr;-estradiol for moderate to severe vasomotor symptoms in postmenopausal women

Drospirenone 0.25 mg/17&bgr;-estradiol 0.5 mg is concluded to be the lowest dose with demonstrated efficacy in the treatment of postmenopausal women with moderate to severe vasomotor symptoms.

for the treatment of vasomotor symptoms associated with menopause

Estradiol gel 0.1% (Divigel ®) is a low-dose, ‘patchless’ transdermal formulation of a bioidentical estrogen that has been demonstrated to be effective and well tolerated in the treatment of moderateto-severe hot flushes.

Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women

Pulsed estrogen therapy, achieved by intranasal estradiol 150 μg/day and 300 μg/ day, significantly reduced the incidence of moderate to severe vasomotor symptoms, compared with placebo, and therefore offers the best efficacy/safety ratio when initiating treatment with intranAsal Estradiol.

Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.

ERr 731 was confirmed to be effective for the treatment of menopausal symptoms in perimenopause and well tolerated by the majority of women.



Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms?

While both combinations resulted in similar bleeding profiles in postmenopausal women, the combination of 1 mg E2/0.5 mg NETA resulted in the lowest incidence of bleeding in late perimenopausal women.

Oral Menopausal Therapy Using 17-β Micronized Estradiol: A Preliminary Study of Effectiveness, Tolerance and Patient Preference

A new dosage form of pure 17-β Estradiol, micronized for better absorption, was not only well tolerated but also clinically effective in this preliminary study of menopausal therapy.

Micronized 17β-Estradiol for Oral Estrogen Therapy in Menopausal Women

Micronized 17β-estradiol (E2) was used as oral replacement therapy in 369 patients with estrogen deficiency and related menopausal symptoms and gained satisfactory relief of their symptoms from cyclic E2 therapy.

Estrace vs Premarin for treatment of menopausal symptoms: Dosage comparison study

  • Adv Ther 1992;9:21–31
  • 1992